Mesoblast Ltd

Mesoblast Limited is an Australian company that develops regenerative medicine products through its subsidiaries. Its proprietary platform is based on specialized mesenchymal lineage cells. The company's pipeline includes remestemcel-L-rknd in Phase III trials for systemic inflammatory diseases, Remestemcel-L in Phase III trials for chronic heart failure and chronic low back pain, and Revascor for hypoplastic left heart syndrome. It also develops MPC-300-IV, MPC-150-IM, Ryoncil, and MPC-25-IC, and has strategic partnerships with Tasly Pharmaceutical Group, Grünenthal GmbH, and JCR Pharmaceuticals. Mesoblast was incorporated in 2004 and is headquartered in Melbourne, Australia.